Open Access

Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy

  • Authors:
    • Liang Li
    • Shuchen Liu
    • Liyuan Liu
    • Zhongbing Ma
    • Man Feng
    • Chunmiao Ye
    • Wenzhong Zhou
    • Yongjiu Wang
    • Lu Liu
    • Fei Wang
    • Lixiang Yu
    • Fei Zhou
    • Yujuan Xiang
    • Shuya Huang
    • Qinye Fu
    • Qiang Zhang
    • Dezong Gao
    • Zhigang Yu
  • View Affiliations

  • Published online on: August 7, 2018     https://doi.org/10.3892/etm.2018.6584
  • Pages: 2949-2959
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The expression of insulin‑like growth factor‑1 receptor (IGF‑1R), which is involved in the genesis and progression of breast cancer, is thought to be associated with the overall survival (OS) of patients. However, the predictive and prognostic significance of the IGF‑1R expression in breast cancer remains controversial. The present study aimed to identify the factors associated with the levels of phosphorylated (p)‑IGF‑1R in breast cancer, their impact on the outcomes of breast cancer patients, and the prognostic value of alterations of p‑IGF‑1R during neoadjuvant chemotherapy (NAC). The present study included 348 female breast cancer patients whose paraffin‑embedded tumor tissue sections had been collected by biopsy and/or resection, among which the pre‑NAC and post‑NAC sections were available from 40 patients. Human epidermal growth factor receptor 2 (HER2) positivity and molecular subtype were significantly associated with the presence of p‑IGF‑1R in the tumor tissue (P<0.05). Patients with p‑IGF‑1R present in the tumor tissue had a shorter OS (P=0.003). The p‑IGF‑1R levels in the tumor after NAC differed significantly from those prior to NAC (P=0.005); however, this alteration in p‑IGF‑1R levels was not associated with a shorter OS. In parallel with HER2, p‑IGF‑1R appears to be a promising indicator for predicting clinical outcomes and may be an attractive target for improving the efficacy of antitumor therapy, particularly for patients with HER2‑negative, estrogen receptor‑positive and luminal B tumors.

References

1 

Bray F, Ren JS, Masuyer E and Ferlay J: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, et al: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 4:e10000542008. View Article : Google Scholar : PubMed/NCBI

3 

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12:236–244. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL, Carroll JS, et al: Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Res. 76:5881–5893. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Weigel MT and Dowsett M: Current and emerging biomarkers in breast cancer: Prognosis and prediction. Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Zeng H, Zheng R, Zhang S, Zou X and Chen W: Female breast cancer statistics of 2010 in China: Estimates based on data from 145 population-based cancer registries. J Thorac Dis. 6:466–470. 2014.PubMed/NCBI

8 

Becker MA, Ibrahim YH, Cui X, Lee AV and Yee D: The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol. 25:516–528. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Sarfstein R, Pasmanik-Chor M, Yeheskel A, Edry L, Shomron N, Warman N, Wertheimer E, Maor S, Shochat L and Werner H: Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem. 287:2766–2776. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Giovannucci E: Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res. 51 Suppl 3:S34–S41. 1999.

11 

Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, et al: High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One. 4:e72732009. View Article : Google Scholar : PubMed/NCBI

12 

Kucab JE and Dunn SE: Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis. 17:41–47. 2003. View Article : Google Scholar : PubMed/NCBI

13 

Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, Solomides C, Peiper SC and Witkiewicz AK: Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 118:3484–3493. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Farabaugh SM, Boone DN and Lee AV: Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. Front Endocrinol (Lausanne). 6:592015.PubMed/NCBI

15 

Christopoulos PF, Msaouel P and Koutsilieris M: The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 14:432015. View Article : Google Scholar : PubMed/NCBI

16 

Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID and Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 53:3736–3740. 1993.PubMed/NCBI

17 

Bahhnassy A, Mohanad M, Shaarawy S, Ismail MF, El-Bastawisy A, Ashmawy AM and Zekri AR: Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: Prognostic and predictive markers in triple-negative and non-triple-negative breast cancer. Mol Med Rep. 12:851–864. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Kelly GM, Buckley DA, Kiely PA, Adams DR and O'Connor R: Serine phosphorylation of the insulin-like growth factor I (IGF-1) receptor C-terminal tail restrains kinase activity and cell growth. J Biol Chem. 287:28180–28194. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, et al: Breast cancer version 2.2015. J Natl Compr Canc Netw. 13:448–475. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH, van der Graaf WT and Wesseling J: Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat. 129:725–736. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC and Kennecke H: Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat. 132:131–142. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI

23 

Friedrichs K, Gluba S, Eidtmann H and Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer. 72:3641–3647. 1993. View Article : Google Scholar : PubMed/NCBI

24 

Zhao S, Chen SS, Gu Y, Jiang EZ and Yu ZH: Expression and clinical significance of sushi domain-containing protein 3 (SUSD3) and insulin-like growth factor-I receptor (IGF-IR) in breast cancer. Asian Pac J Cancer Prev. 16:8633–8636. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Wauters CA, Strobbe LJ, Mandigers CM, Bult P, Oyen WJ, van der Graaf WT and van Laarhoven HW: Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. PLoS One. 10:e01177452015. View Article : Google Scholar : PubMed/NCBI

26 

Mauro L, Naimo GD, Ricchio E, Panno ML and Andò S: Cross-Talk between adiponectin and IGF-IR in breast cancer. Front Oncol. 5:1572015. View Article : Google Scholar : PubMed/NCBI

27 

Surmacz E: Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 22:6589–6597. 2003. View Article : Google Scholar : PubMed/NCBI

28 

Su B, Wong C, Hong Y and Chen S: Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms. J Steroid Biochem Mol Biol. 123:101–108. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, et al: Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 132:61–73. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J and O'Driscoll L: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 13:712014. View Article : Google Scholar : PubMed/NCBI

31 

Ye XM, Zhu HY, Bai WD, Wang T, Wang L, Chen Y, Yang AG and Jia LT: Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer. 14:1342014. View Article : Google Scholar : PubMed/NCBI

32 

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI

33 

Nahta R, Yuan LX, Zhang B, Kobayashi R and Esteva FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65:11118–11128. 2005. View Article : Google Scholar : PubMed/NCBI

34 

Chen C, Zhang Y, Zhang Y, Li J, Tsao SW and Zhang MY: Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Mol Cancer Ther. 13:90–100. 2014. View Article : Google Scholar : PubMed/NCBI

35 

Papa A, Caruso D, Tomao S, Rossi L, Zaccarelli E and Tomao F: Triple-negative breast cancer: Investigating potential molecular therapeutic target. Expert Opin Ther Targets. 19:55–75. 2015. View Article : Google Scholar : PubMed/NCBI

36 

Mancini P, Angeloni A, Risi E, Orsi E and Mezi S: Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel). 6:2187–2223. 2014. View Article : Google Scholar : PubMed/NCBI

37 

Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, et al: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 19:5533–5540. 2013. View Article : Google Scholar : PubMed/NCBI

38 

Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y: Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. Hum Pathol. 35:1537–1542. 2004. View Article : Google Scholar : PubMed/NCBI

39 

Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68:10238–10246. 2008. View Article : Google Scholar : PubMed/NCBI

40 

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2018
Volume 16 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, L., Liu, S., Liu, L., Ma, Z., Feng, M., Ye, C. ... Yu, Z. (2018). Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy. Experimental and Therapeutic Medicine, 16, 2949-2959. https://doi.org/10.3892/etm.2018.6584
MLA
Li, L., Liu, S., Liu, L., Ma, Z., Feng, M., Ye, C., Zhou, W., Wang, Y., Liu, L., Wang, F., Yu, L., Zhou, F., Xiang, Y., Huang, S., Fu, Q., Zhang, Q., Gao, D., Yu, Z."Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy". Experimental and Therapeutic Medicine 16.4 (2018): 2949-2959.
Chicago
Li, L., Liu, S., Liu, L., Ma, Z., Feng, M., Ye, C., Zhou, W., Wang, Y., Liu, L., Wang, F., Yu, L., Zhou, F., Xiang, Y., Huang, S., Fu, Q., Zhang, Q., Gao, D., Yu, Z."Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy". Experimental and Therapeutic Medicine 16, no. 4 (2018): 2949-2959. https://doi.org/10.3892/etm.2018.6584